References
- Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., … Group, C. T. (2010). Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science, 329(5996), 1168–1174. doi: 10.1126/science.1193748
- AIDS Vaccine Advocacy Coalition. (2016). Ongoing and planned PrEP demonstration and implementation studies. Retrieved January 27, 2017, from http://www.avac.org/resource/ongoing-and-planned-prep-demonstration-and-implementation-studies
- Azim, T., Bontell, I., & Strathdee, S. A. (2015). Women, drugs and HIV. International Journal of Drug Policy, 26(Suppl 1), S16–21. doi: 10.1016/j.drugpo.2014.09.003
- Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., … Bangkok Tenofovir Study, G. (2013). Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok tenofovir study): A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, 381(9883), 2083–2090. doi: 10.1016/S0140-6736(13)61127-7
- Greene, E., Batona, G., Hallad, J., Johnson, S., Neema, S., & Tolley, E. E. (2010). Acceptability and adherence of a candidate microbicide gel among high-risk women in Africa and India. Culture, Health & Sexuality, 12(7), 739–754. doi: 10.1080/13691051003728599
- Guise, A., Albers, E. R., & Strathdee, S. A. (2016). “Prep is not ready for our community, and our community is not ready for PrEP”: Pre-exposure prophylaxis for HIV for people who inject drugs and limits to the HIV prevention response. Addiction (Abingdon, England). doi: 10.1111/add.13437
- Guise, A., Dimova, M., Ndimbii, J., Clark, P., & Rhodes, T. (2015). A qualitative analysis of transitions to heroin injection in Kenya: Implications for HIV prevention and harm reduction. Harm Reduction Journal, 12, 441. doi: 10.1186/s12954-015-0061-2
- Luecke, E. H., Cheng, H., Woeber, K., Nakyanzi, T., Mudekunye-Mahaka, I. C., van der Straten, A., & Team, M.-D. S. (2016). Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D (MTN-003D) study. Journal of the International AIDS Society, 19(1), 20875. doi: 10.7448/IAS.19.1.20875
- National AIDS & STI Control Program. (2016). Guidelines on Use of antiretroviral drugs for treating and preventing HIV infections in Kenya. Nairobi: Ministry of Health of Kenya. Retrieved August 3, 2017, from http://www.faces-kenya.org/wp-content/uploads/2016/07/Guidelines-on-Use-of-Antiretroviral-Drugs-for-Treating-and-Preventing-HI....pdf
- Nel, A., van Niekerk, N., Kapiga, S., Bekker, L. G., Gama, C., Gill, K., … Ring Study, T. (2016). Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. New England Journal of Medicine, 375(22), 2133-2143. doi: 10.1056/NEJMoa1602046
- Ryan, G. W., & Bernard, H. R. (2003). Techniques to identify themes. Field Methods, 15(1), 85–109. doi: 10.1177/1525822X02239569
- Syvertsen, J. L., Bazzi, A. M. R., Scheibe, A., Adebajo, S., Strathdee, S. A., & Wechsberg, W. M. (2014). The promise and peril of pre-exposure prophylaxis (PrEP): using social science to inform PrEP interventions among female sex workers. African Journal of Reproductive Health, 18(3), 74–83.
- Syvertsen, J. L., Ohaga, S., Agot, K., Dimova, M., Guise, A., Rhodes, T., & Wagner, K. D. (2016). An ethnographic exploration of drug markets in kisumu, Kenya. International Journal of Drug Policy, 30, 82–90. doi: 10.1016/j.drugpo.2016.01.001
- Van der Elst, E. M., Mbogua, J., Operario, D., Mutua, G., Kuo, C., Mugo, P., … Sanders, E. J. (2013). High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: Qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS and Behavior, 17(6), 2162–2172. doi: 10.1007/s10461-012-0317-8
- World Health Organization. (2016). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach (2nd ed.). Geneva, Switzerland: World Health Organization. Retrieved August 3, 2017, from http://www.who.int/hiv/pub/arv/arv-2016/en/